Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
STAR Protocols|March 26, 2025
An optimized protocol for generating fibrotic murine precision-cut lung slicesStefanos Smyrniotis, Paraskevi Kanellopoulou, Christiana Magkrioti, et al.
Expert Opinion on Therapeutic Targets|February 22, 2025
Pharmacological targeting of ECM homeostasis, fibroblast activation and invasion for the treatment of pulmonary fibrosisIoannis Tomos, Paraskevi Kanellopoulou, Dimitris Nastos, et al.
Journal of Autoimmunity|September 1, 2019
Autotaxin and chronic inflammatory diseasesChristiana Magkrioti, Apostolos Galaris, Paraskevi Kanellopoulou, et al.
International Journal of Molecular Sciences|July 27, 2022
Autotaxin Has a Negative Role in Systemic InflammationIoanna Nikitopoulou, Aggeliki Katsifa, Paraskevi Kanellopoulou, et al.
Frontiers in Medicine|September 25, 2023
Increased lipocalin-2 expression in pulmonary inflammation and fibrosisApostolos Galaris, Dionysios Fanidis, Eliza Tsitoura, et al.
Nature Communications|September 21, 2023
SRC and TKS5 mediated podosome formation in fibroblasts promotes extracellular matrix invasion and pulmonary fibrosisIlianna Barbayianni, Paraskevi Kanellopoulou, Dionysios Fanidis, et al.
Journal of Medicinal Chemistry|October 5, 2023
<i>N</i>-(2-Aminophenyl)-benzamide Inhibitors of Class I HDAC Enzymes with Antiproliferative and Antifibrotic ActivityDimitrios Triantafyllos Gerokonstantis, Christiana Mantzourani, Dimitrios Gkikas, et al.
Nature Communications|January 21, 2026
Versican expression from lung fibroblasts suppresses pulmonary fibrosisParaskevi Kanellopoulou, Ilianna Barbayianni, Dionysios Fanidis, et al.
Respiratory Research|November 14, 2023
Expression of PD-1/PD-L1 axis in mediastinal lymph nodes and lung tissue of human and experimental lung fibrosis indicates a potential therapeutic target for idiopathic pulmonary fibrosisTheodoros Karampitsakos, Apostolos Galaris, Serafeim Chrysikos, et al.
Cell Reports. Medicine|May 1, 2026
An aerosolized dual-action autotaxin inhibitor-PPARγ agonist for the treatment of pulmonary fibrosisAlexios N Matralis, Elli-Anna Stylianaki, Eleni M Ladopoulou, et al.
Pageof 1